Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H. Mayer, Lindsey R. Baden, Benigno Rodríguez et al.|PLoS Medicine|2017Cited by 132
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R. Baden, Hong‐Van Tieu, Daniel J Stieh et al.|The Lancet HIV|2020Cited by 91
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK. Rachael Parks, M. Juliana McElrath, Zoe Moodie et al.|Science Translational Medicine|2025Cited by 40
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Varun K. Phadke, Dan H. Barouch et al.|The Journal of Infectious Diseases|2022Cited by 36
Antigenic competition in CD4 <sup>+</sup> T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trialEsper G. Kallás, Nicole Frahm, Nicole Grunenberg et al.|Science Translational Medicine|2019Cited by 27